Hypertension increases the risk of reinfarction and sudpotentially be met by use of ACE inhibitors. However, achieving quality BP control demands appropriate den death in the post-myocardial infarction patient, and the same also applies to the co-existing left ventricular selection of doses and dosage regimens. Trough : peak ratios are useful in determining duration of action and hypertrophy (LVH). Thus the therapeutic aim in such patients are: (1) appropriate blood pressure (BP) conmay thus offer a rational approach to aid the selection drug doses and dosage regimens. trol; (2) regression of LVH; and (3) secondary prevention to reduce long-term mortality. All of these goals can Keywords: trough:peak ratio; antihypertensive response; post MI; heart failure; 24-h blood pressure control may be a manifestation of severe myocardial ischae-
Introduction mia and/or hypertension. Accurate identification of subsets of high risk
It may thus be reasonably suggested that the optipatients following hospitalisation for acute myocarmal therapeutic strategy in the hypertensive post-MI dial infarction (MI) and heart failure is vital for propatients are as follows: per management, both acutely and in the long term.
1
(1) adequate control of BP to prevent target organ Stratification of risk is important, particularly durdamage; ing the first year after acute MI, as this is the period (2) regression of left ventricular hypertrophy; in which the risk of recurrent infarction and sudden (3) secondary prevention to reduce long-term mordeath is highest. Long-term outcome after acute MI tality and the incidence of non-fatal MI. is influenced by a variety of factors of which the most notable are significant left ventricular dysfuncThe first two of these therapeutic goals are equally tion, residual myocardial ischaemia and serious applicable to the treatment of hypertension in the ventricular arrhythmia. Systemic hypertension is a uncomplicated hypertensive patient. major risk factor that contributes to the development of myocardial ischaemia and congestive heart failure Optimal BP control (CHF) in the context of acute MI. A previous history of hypertension results in a poorer prognosis in Established epidemiological data has been utilised patients with acute MI with one-third of such to suggest an optimal approach to BP control. 4 This patients dying and one-quarter developing reinfarchypothesis is based upon the following obsertion during the first year after the onset of acute MI.
vations:
In addition, a long-term follow-up survival study of
(1) measures of 24-h BP more closely correlate with men screened for the MRFIT study indicated that a wide range of different measures of hypertenthe major blood pressure (BP)-associated risk in MI sion-related target organ damage than do casual survivors is attributable to high rather than low BP. 3 BP measurements made in the clinic or office; Thus, at least in theory, the potentially remediable (2) there is a higher incidence of cardiovascular character of hypertension is important when efforts complications when night time BP remains high; to reduce post-MI morbidity and mortality are con-(3) BP variability itself is an independent determisidered. Whilst in general, hypotension is more nant of target organ damage; common than hypertension in post-MI patients with (4) the incidence of cardiovascular events peaks in impaired systolic left ventricular (LV) function. In the morning around the time of awakening when contrast, diastolic dysfunction is characterised by there is a 'surge' in BP from the inherently low the presence of CHF with preserved LV function and night time levels to the high levels achieved during the waking day.
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should be based upon strategies that consistently reduce BP over a full 24-h period without increasing variability in BP itself. 4 In essence, this is most likely to be achieved using drugs that offer long duration of action. A large number of antihypertensive agents have been licensed for once daily administration and on that basis, it might be assumed that all offered this desirable characteristic, of smooth, consistent and sustained BP control. In practice, this is clearly not the case, and the problem has been to identify agents that consistently achieve this 'ideal' characteristic. The application of 24-h ambulatory BP monitoring appears to offer a mechanism by which such agents could be identified. However, in practice, whilst this approach does undoubtedly yield important information, it is often the case that both the inherent variability in measuring BP in this way, the volume of data generated and the appli- obscure the definition of a simple index of antihypertensive efficacy that can differentiate between alternative therapeutic strategies.
ing interval, relative to placebo, immediately prior to the administration of the next dose ( Figure 1 ). It is important to appreciate that trough does not
Trough : peak ratio
necessarily correspond to the minimum effect elicited by the drug over a dosage interval, as this often Trough : peak (T : P) ratio is a relatively recent addition to a list of parameters characterising the occurs during the night time when the patient is asleep and BP is inherently lower, even under pladuration of action of an antihypertensive drug over the recommended dosage interval. The concept cebo conditions. The definition of peak BP response may prove more difficult to define because allowarose from the considerations of the 'Cardio-Renal Drug Advisory Committee of the US Food & Drug ance must be made, not only for the underlying circadian/placebo BP variability, but also the interAdministration' (FDA) in the late 1980s. The FDA met to formulate a series of guidelines related to the individual variability in the time at which peak hypertensive response occurs. Therefore, by defidevelopment of new antihypertensive agents, and those relating to T : P ratio were proposed largely for nition there is no standardised time after dosing for measurement of peak response, and peak is defined reasons of safety. The concern was that comparatively short-acting drugs were having their duration as the maximum BP difference between placebo and drug treatments, regardless of the time post-dose and of action prolonged by the simple expedient of selecting doses that were larger than necessary or desirshould not be confused with the lowest BP achieved on active therapy (Figure 1 ). able. It was recognised that such doses might lead to an excessive fall in BP around the time of peak
The potential advantage of T : P ratio in assessment of duration of action is that it avoids the pitresponse with the potential concomitant risk of impaired critical organ perfusion (eg, cerebral blood falls of established practice in clinical trials performed for licensing purposes where attention has been flow), risk of symptomatic lightheadedness, syncope or possible thrombotic stroke. The guidelines on focussed solely upon the BP 'control' at a single time-point at the end of the dosage interval. Thus, T : P ratio indicated that, during steady-state treatment, any antihypertensive drug should retain most in the past, two agents may have been deemed to be equipotent and equally effective in controlling BP of its peak BP lowering effect over the dosage interval, and specifically the trough effect should be no when administered once-daily, simply by virtue of the fact that they achieve the same BP control at less than half of the peak effect. An additional caveat was incorporated into the Guidelines to the effect trough. However, one agent may achieve this control by virtue of a relatively smooth and consistent patthat if a drug elicited a relatively modest BP response at trough, 5 mm Hg for example, then a tern of BP control whereas the other may only achieve 'control' at trough by virtue of a profound fall larger T : P ratio of 66% would be required.
The fundamental concepts underlying the defiin BP at peak. Inappropriate reliance upon assessment of drug effect and titration of doses, based nition of T : P ratio are illustrated in Figure 1 , which highlights some of the factors which are of paraupon trough BP responses, has been well illustrated in a study with the relatively short-acting dihydropmount importance in the definition of T : P ratio. For example, the original Guidelines explicitly sugyridine calcium antagonist, isradipine. 6 The investigators in this study noted that some patients, who gested that any definition of T : P ratio must make allowance for placebo circadian effects, and it has had undergone dose titration, guided by clinic BP measurements taken at trough, showed evidence of been well demonstrated that failure to take account of the placebo effect can entirely alter the interpretprofound hypotension 2-3 h after drug administration, when they had their BP monitored by ambuation of the results. 5 Identification of the trough effect is relatively straightforward, as this is defined latory means. When the same patients had their dose reduced to avoid this hypotensive response, BP was as being the effect at the end of the steady-state dos-poorly controlled at the end of the dosage interval. 6 daily (Table I) . Indeed, only three of these studies have utilised once daily administration and of these This serves to highlight the potential differences between the practice adopted in clinical trials for CONSENSUS-II failed to demonstrate any clinical benefit. licensing purposes, and clinical practice itself. In general, clinical decisions regarding the adequacy of As well as highlighting the potential deficiencies of many ACE inhibitors as once daily antihyperten-BP control are made on the basis of clinic BP measurements, made at some time during the worksive agents, the study by Zannad 8 suggested that, in some instances, the T : P ratio for ACE inhibitors ing day. These BPs are more likely to correspond with the time of peak antihypertensive effect elicmay be dose-dependent. For example, the quoted range of T : P ratio for lisinopril was 40-80% and ited by the drug, assuming that the patient takes the dose first thing in the morning. Thus, titration of whilst undoubtedly such discrepant values may reflect differences in underlying methodology, it drug effect will occur around the time of peak BP response, and this may result in a decision being may also reflect the dose-dependent differences in T : P ratio. For example, there is clear evidence from made to reduce the dose of a drug to moderate the response at peak on the assumption that the dose ranging studies that T : P ratio for lisinopril is indeed dose-dependent 9 and this is illustrated in measurement in the clinic represents the control of BP throughout the dosage interval. In practice, if a Figure 2a . It is important to note from this Figure that the change in T : P ratio occurs over the recdrug has a relatively modest T : P ratio, the consequences of this may well be a failure to control BP ommended therapeutic dosage range for the treatment of hypertension, such that the lowest dose at the end of the dosage interval and, assuming morning dosing, this would result in a failure to which might be recommended for initiation of treatment will have a sub-optimal T : P ratio, whereas the blunt the early morning BP 'surge', which is often associated with a peak in cardiovascular events. 4 higher maintenance dose of 20 mg will have an acceptable T : P ratio. This creates a practical problem for the prescribing physician, in that the lowest
T : P ratio and 24-h BP
and highest dose are both recommended as being suitable for once daily administration. This Although the definition of T : P ratio was largely proposed on the basis of safety, the evidence sugphenomenon, however, is not exhibited with all ACE inhibitors; this is highlighted in Figure 2b for gests that the parameter provides useful information about the consistency of antihypertensive response trandolapril, which illustrates a clear dose-response relationship for both trough and peak BP responses, throughout a dosage interval, and the suitability or otherwise of a drug for providing consistent 24-h BP control. However, it is clear that for any given antihypertensive agent, the T : P ratio is not identified by any single numerical value, and is subject to inter-patient variability. The T : P ratio is also directly dependent upon the selected dosage interval, and a drug deemed to be sub-optimal for once daily administration, may have a perfectly acceptable T : P ratio when administered twice daily. For example, the ACE inhibitor, enalapril, has been reported to have a T : P ratio of less than 50% when administered at 20 mg once daily, but a ratio of approximately 70% when administered in doses of 5 and 10 mg twice daily. 7 Use of the twice daily dosing regimen resulted, not only in the avoidance of the pronounced peak effect associated with once daily administration, but also superior BP control (as assessed by the average 24-h BP) with both twice daily regimens, despite in one case using a lower total daily dose.
The relative failure of enalapril to produce 'quality' BP control when administered once a day is a property which apparently is shared by a number of ACE inhibitors. This was illustrated in a quasi-metaanalysis 8 which calculated T : P ratios for a number of different ACE inhibitors and showed that many of the non-thiol ACE inhibitors failed to achieve T : P ratios in excess of 50% when administered once daily. Furthermore, given that ACE inhibitors appear to offer additional benefit in terms of secondary prevention, not solely associated with BP reduction, it is noteworthy that the majority of outcome studies post-MI with ACE inhibitors have relied upon drug administration more than once but does not exhibit a dose-dependency in T : P ratio when ranging from doses below and through the therapeutic range.
Therapeutic coverage and T : P ratio
If T : P ratio provides a useful index of duration of action over the dosage interval, it is reasonable to postulate that it also provides information concerning the effectiveness of a drug beyond its dosage interval, and its continuing duration of action, if a dose is omitted or taken belatedly. This is obviously of particular importance in the poorly compliant patient, and whilst there is evidence that compliance with once daily dosing regimens is superior to that of twice daily dosing regimens, 10 the difference is not substantial. Thus, for relatively shortacting drugs, with poor T : P ratios, the benefits of slight improvement in compliance with once daily administration are unlikely to be clinically justified when the effects of dosage omissions are taken into account. With the relatively high incidence of missed and belated dosing, reported in hypertensive patients during prolonged therapy, 11 it is reasonable to anticipate that a drug with a high T : P ratio, relative to its recommended dosage interval, will sustain a significant antihypertensive effect beyond the end of the steady-state dosage interval. This theoretical consideration has been supported by the evi- omission. A parallel group comparison of the effectiveness of enalapril and trandolapril to control BP pendent of the effect on BP. There is now following a missed dose is illustrated in Figure 3a convincing evidence that where appropriately and 3b. 12 Two features are apparent in these Figures; characterised, T : P ratio is a useful index of the durfirstly, trandolapril is able to sustain a more consistation of antihypertensive action. 14 A 'satisfactory' ent BP control over the first 24-h period, whereas T : P ratio indicates that the duration of effect of an there are more dosing-related fluctuations in the BP antihypertensive drug is appropriate for the chosen profile with enalapril, this being entirely consistent dosage interval. It further indicates that the control with the relative T : P ratios of these compounds. of BP will be consistently maintained throughout Secondly, the two agents are disparate with respect the dosage inteval, and that there will be some conto their ability to control BP beyond the end of the sistency of the antihypertensive effect beyond the dosage interval, such that whilst with both agents end of the dosage interval, even if the patient is there is a diminution of effect, in the period 24 -irregularly compliant. It is clear that many existing 48 h, this is more pronounced with enalapril which established once daily antihypertensive treatment does not exhibit any antihypertensive effect in the regimens do not meet the minimum requirement of final few hours of observation, which corresponds a T : P ratio exceeding 50%. In other instances, this with the time of the early morning rise in BP followthreshold can only be achieved by increments in ing a missed dose, whilst in contrast there is still dosage, which is not only contrary to the original some degree of BP control achieved at this time by intent of the FDA Guidelines, but is also inappropritrandolapril (Figure 3a and 3b) .
ate, therapeutically. Whilst there is no definitive outcome data either in uncomplicated hypertension or in the post-MI patient, it is likely that drug treatConclusion ment regimens, which can consistently produce The principles underlying good therapeutic practice T : P ratios over 70% throughout the recommended in the treatment of hypertension, in the post-MI dosage range, are likely to offer significant therapatient, is entirely consistent with that in the peutic advantage. uncomplicated essential hypertensive. Primarily, the aim should be to achieve smooth and consistent
